FY2021 EPS Estimates for Exelixis, Inc. Raised by Truist Securities (NASDAQ:EXEL)

Exelixis, Inc. (NASDAQ:EXEL) – Analysts at Truist Securities boosted their FY2021 EPS estimates for shares of Exelixis in a research report issued to clients and investors on Tuesday, January 11th. Truist Securities analyst A. Goonewardene now forecasts that the biotechnology company will post earnings of $0.46 per share for the year, up from their previous forecast of $0.42. Truist Securities currently has a “Buy” rating and a $36.00 price target on the stock. Truist Securities also issued estimates for Exelixis’ Q4 2021 earnings at $0.04 EPS, FY2022 earnings at $0.88 EPS, FY2023 earnings at $1.22 EPS, FY2024 earnings at $1.56 EPS, FY2025 earnings at $1.99 EPS and FY2026 earnings at $2.36 EPS.

Exelixis (NASDAQ:EXEL) last released its earnings results on Tuesday, November 2nd. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.19 by ($0.07). The firm had revenue of $328.42 million during the quarter, compared to analysts’ expectations of $366.34 million. Exelixis had a net margin of 13.10% and a return on equity of 8.27%. During the same quarter last year, the company posted ($0.10) earnings per share.

Several other research analysts have also weighed in on EXEL. TheStreet lowered shares of Exelixis from a “b-” rating to a “c” rating in a report on Thursday, November 4th. Oppenheimer cut their price objective on shares of Exelixis from $30.00 to $29.00 and set an “outperform” rating on the stock in a report on Tuesday, November 2nd. Royal Bank of Canada cut their price objective on shares of Exelixis from $32.00 to $31.00 and set an “outperform” rating on the stock in a report on Wednesday, November 3rd. Zacks Investment Research lowered shares of Exelixis from a “buy” rating to a “sell” rating and set a $23.00 price objective on the stock. in a report on Monday, November 8th. Finally, Jefferies Financial Group assumed coverage on shares of Exelixis in a research report on Wednesday, October 6th. They set a “buy” rating and a $28.00 target price for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, Exelixis has a consensus rating of “Buy” and a consensus target price of $32.18.

NASDAQ:EXEL opened at $18.12 on Thursday. The firm has a market cap of $5.73 billion, a price-to-earnings ratio of 35.53, a price-to-earnings-growth ratio of 0.57 and a beta of 0.89. Exelixis has a 12-month low of $15.50 and a 12-month high of $25.77. The company’s 50-day moving average is $17.86 and its two-hundred day moving average is $18.80.

Hedge funds have recently added to or reduced their stakes in the company. Baillie Gifford & Co. acquired a new stake in shares of Exelixis during the third quarter worth approximately $25,000. Total Clarity Wealth Management Inc. acquired a new stake in shares of Exelixis during the third quarter worth approximately $26,000. Huntington National Bank grew its position in shares of Exelixis by 156.4% during the third quarter. Huntington National Bank now owns 1,433 shares of the biotechnology company’s stock worth $30,000 after buying an additional 874 shares in the last quarter. MUFG Americas Holdings Corp bought a new position in Exelixis during the third quarter worth $30,000. Finally, Advisory Services Network LLC bought a new position in Exelixis during the second quarter worth $43,000. 82.96% of the stock is owned by institutional investors and hedge funds.

In other news, EVP Peter Lamb sold 47,500 shares of the firm’s stock in a transaction that occurred on Monday, November 15th. The shares were sold at an average price of $18.09, for a total transaction of $859,275.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Jeffrey Hessekiel sold 5,117 shares of the firm’s stock in a transaction that occurred on Monday, November 1st. The stock was sold at an average price of $22.03, for a total transaction of $112,727.51. The disclosure for this sale can be found here. Insiders sold 137,353 shares of company stock valued at $2,450,124 in the last ninety days. 3.30% of the stock is owned by corporate insiders.

About Exelixis

Exelixis, Inc is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of COMETRIQ, CABOMETYX, COTELLIC, and MINNEBRO. The company was founded by Corey S. Goodman and Stelios B.

Read More: What is Elliott Wave theory?

Earnings History and Estimates for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.